The pharmacological modulations of both PPAR-α and -γ as therapeutic treatmentsfor diabetes and hyperlipidemia have been linked to an improvement on the low-gradeinflammation associated with these conditions [4, 5]. This evidence concerns the gene PPARA and hyperlipidemia.